JPWO2022011391A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022011391A5 JPWO2022011391A5 JP2023501229A JP2023501229A JPWO2022011391A5 JP WO2022011391 A5 JPWO2022011391 A5 JP WO2022011391A5 JP 2023501229 A JP2023501229 A JP 2023501229A JP 2023501229 A JP2023501229 A JP 2023501229A JP WO2022011391 A5 JPWO2022011391 A5 JP WO2022011391A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- degrees
- free base
- base form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012458 free base Substances 0.000 claims description 35
- 229940126062 Compound A Drugs 0.000 claims description 19
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 19
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 10
- 238000001757 thermogravimetry curve Methods 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 6
- 201000010881 cervical cancer Diseases 0.000 claims 6
- 206010046766 uterine cancer Diseases 0.000 claims 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010047741 Vulval cancer Diseases 0.000 claims 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000000649 small cell carcinoma Diseases 0.000 claims 4
- 206010046885 vaginal cancer Diseases 0.000 claims 4
- 208000013139 vaginal neoplasm Diseases 0.000 claims 4
- 201000005102 vulva cancer Diseases 0.000 claims 4
- 238000001228 spectrum Methods 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 2
- 206010046392 Ureteric cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical group OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 150000003840 hydrochlorides Chemical group 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 2
- 150000003839 salts Chemical group 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000011294 ureter cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- OXTSYWDBUVRXFF-GDLZYMKVSA-N 1-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one Chemical compound C1=C2C(=NC(N3C4=NC(NC5=CC=C(C=C5)N5CCN(CC5)C)=NC=C4C(=O)N3CC=C)=C1)[C@@](CC)(CC2)O OXTSYWDBUVRXFF-GDLZYMKVSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical group OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 125000005490 tosylate group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025156853A JP2025181949A (ja) | 2020-07-09 | 2025-09-22 | Ｗｅｅ１阻害剤の塩及び形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049996P | 2020-07-09 | 2020-07-09 | |
| US63/049,996 | 2020-07-09 | ||
| PCT/US2021/070851 WO2022011391A1 (en) | 2020-07-09 | 2021-07-08 | Salts and forms of a wee1 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156853A Division JP2025181949A (ja) | 2020-07-09 | 2025-09-22 | Ｗｅｅ１阻害剤の塩及び形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533040A JP2023533040A (ja) | 2023-08-01 |
| JPWO2022011391A5 true JPWO2022011391A5 (https=) | 2024-07-17 |
| JP2023533040A5 JP2023533040A5 (https=) | 2024-07-17 |
Family
ID=79552745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501229A Pending JP2023533040A (ja) | 2020-07-09 | 2021-07-08 | Ｗｅｅ１阻害剤の塩及び形態 |
| JP2025156853A Pending JP2025181949A (ja) | 2020-07-09 | 2025-09-22 | Ｗｅｅ１阻害剤の塩及び形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156853A Pending JP2025181949A (ja) | 2020-07-09 | 2025-09-22 | Ｗｅｅ１阻害剤の塩及び形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606567B2 (https=) |
| EP (1) | EP4178960A4 (https=) |
| JP (2) | JP2023533040A (https=) |
| KR (1) | KR20230038523A (https=) |
| CN (1) | CN116323613A (https=) |
| AU (1) | AU2021305347A1 (https=) |
| BR (1) | BR112023000350A2 (https=) |
| CA (1) | CA3188737A1 (https=) |
| MX (1) | MX2023000333A (https=) |
| TW (1) | TWI896701B (https=) |
| WO (1) | WO2022011391A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| CN116462687B (zh) * | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| EP4469086A4 (en) * | 2022-01-25 | 2026-01-21 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| JP2025525935A (ja) * | 2022-08-05 | 2025-08-07 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 子宮漿液性がんを治療するためのｗｅｅ１化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025076311A1 (en) * | 2023-10-06 | 2025-04-10 | Zeno Management, Inc. | Solid forms of a wee1 inhibitor |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2338876A1 (en) * | 2009-12-22 | 2011-06-29 | LEK Pharmaceuticals d.d. | Tamsulosin adipate for pharmaceutical use |
| CA3071405A1 (en) | 2017-08-01 | 2019-02-07 | Recurium Ip Holdings, Llc | 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs |
| MX2020009372A (es) | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
| WO2020210320A1 (en) | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2021127039A1 (en) | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| AU2020407070A1 (en) | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| MX2022007623A (es) | 2019-12-20 | 2022-09-23 | Recurium Ip Holdings Llc | Combinaciones. |
| BR112022012280A2 (pt) | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| AU2021271844A1 (en) | 2020-05-15 | 2022-12-08 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
| WO2021242667A1 (en) | 2020-05-28 | 2021-12-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Optical see-through head-mounted lightfield displays based on substrate-guided combiners |
| EP4153591A4 (en) * | 2020-06-11 | 2024-01-24 | Recurium IP Holdings, LLC | METHOD FOR PRODUCING WEE1 INHIBITOR COMPOUNDS |
| WO2022136916A1 (en) | 2020-12-22 | 2022-06-30 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| AU2022259496A1 (en) | 2021-04-12 | 2023-10-12 | Recurium Ip Holdings, Llc | Wee1 compound for treating uterine serous carcinoma |
| WO2022251224A1 (en) | 2021-05-28 | 2022-12-01 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2022271731A1 (en) | 2021-06-23 | 2022-12-29 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2023064282A1 (en) | 2021-10-13 | 2023-04-20 | Recurium Ip Holdings, Llc | Combinations of wee 1 inhibitors and anti-cd47 antibodies. |
| WO2023076485A1 (en) | 2021-10-28 | 2023-05-04 | Recurium Ip Holdings, Llc | Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors |
| EP4447965A4 (en) | 2021-12-15 | 2025-12-03 | Recurium Ip Holdings Llc | COMBINATIONS FOR TRIPLE THERAPY OF BCL-2 INHIBITORS, WEE-1 INHIBITORS AND OTHER CHEMOTHERAPEUTIC AGENTS |
| JP2024546569A (ja) | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | がんに対するｗｅｅ１阻害剤 |
| KR20240119096A (ko) | 2021-12-15 | 2024-08-06 | 리커리엄 아이피 홀딩스, 엘엘씨 | 암 치료를 위한 병용 요법 사용 |
| JP2025525935A (ja) | 2022-08-05 | 2025-08-07 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 子宮漿液性がんを治療するためのｗｅｅ１化合物 |
| EP4587026A1 (en) | 2022-09-15 | 2025-07-23 | Recurium IP Holdings, LLC | Combinations |
| TW202421151A (zh) | 2022-09-16 | 2024-06-01 | 美商瑞卡瑞恩Ｉｐ控股有限責任公司 | Ｗｅｅ１抑制劑及用於治療癌症之方法 |
| EP4615459A4 (en) | 2022-11-08 | 2026-04-29 | Zeno Man Inc | Intermittent dosing regimen for azenosertib in treating cancer |
| KR20250094718A (ko) | 2022-11-08 | 2025-06-25 | 제노 매니지먼트, 인크. | Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도 |
| TW202502354A (zh) | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷（ｈｒｄ）作為預測性生物標記以便使用ｗｅｅ１抑制劑治療癌症 |
| WO2025076311A1 (en) | 2023-10-06 | 2025-04-10 | Zeno Management, Inc. | Solid forms of a wee1 inhibitor |
| WO2025106635A1 (en) | 2023-11-15 | 2025-05-22 | Zeno Management, Inc. | Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors |
| WO2025179038A1 (en) | 2024-02-21 | 2025-08-28 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2025184572A1 (en) | 2024-03-01 | 2025-09-04 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025188946A1 (en) | 2024-03-07 | 2025-09-12 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2025193930A1 (en) | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
-
2021
- 2021-07-08 BR BR112023000350A patent/BR112023000350A2/pt unknown
- 2021-07-08 CN CN202180055999.8A patent/CN116323613A/zh active Pending
- 2021-07-08 CA CA3188737A patent/CA3188737A1/en active Pending
- 2021-07-08 EP EP21838389.1A patent/EP4178960A4/en active Pending
- 2021-07-08 MX MX2023000333A patent/MX2023000333A/es unknown
- 2021-07-08 KR KR1020237004679A patent/KR20230038523A/ko active Pending
- 2021-07-08 AU AU2021305347A patent/AU2021305347A1/en active Pending
- 2021-07-08 US US18/004,628 patent/US12606567B2/en active Active
- 2021-07-08 JP JP2023501229A patent/JP2023533040A/ja active Pending
- 2021-07-08 WO PCT/US2021/070851 patent/WO2022011391A1/en not_active Ceased
- 2021-07-09 TW TW110125370A patent/TWI896701B/zh active
-
2025
- 2025-09-22 JP JP2025156853A patent/JP2025181949A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022011391A5 (https=) | ||
| EP3291814B1 (en) | An anti-cancer agent 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| TWI309647B (https=) | ||
| ES2524161T3 (es) | Preparación de formas hemihidratadas cristalinas de dihidropirazolopirimidinona | |
| JP2022058395A5 (https=) | ||
| TW202033518A (zh) | Kras g12c 抑制劑 | |
| IL283184B2 (en) | Crystal polymorph of (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10] benzoxatriazacyclotridecin–4(5h)–one for the treatment of cancer | |
| JP2019514863A5 (https=) | ||
| CN102232075B (zh) | 氨基吡唑化合物 | |
| JP2007515413A5 (https=) | ||
| JP2013545812A5 (https=) | ||
| RU2013128612A (ru) | Соли и кристаллические формы индуцирующего апоптоз агента | |
| JP2011521968A5 (https=) | ||
| NZ597252A (en) | Compounds for inhibiting mitotic progression | |
| TW201609720A (zh) | １，３，４－噻二唑化合物及其用於治療癌症之用途 | |
| JP2020535168A5 (https=) | ||
| EP3193876A1 (en) | Crystal forms of glutaminase inhibitors | |
| JP2020512315A5 (https=) | ||
| JP2020511468A5 (https=) | ||
| JP2011506274A5 (https=) | ||
| RU2010121647A (ru) | Полиморфы ингибитора c-met/hgfr | |
| JP2008506690A5 (https=) | ||
| CN115702154A (zh) | 一种嘧啶类化合物的盐和晶型及其制备方法 | |
| JPWO2023018237A5 (https=) | ||
| RU2023100213A (ru) | Соли и формы ингибитора wee1 |